DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

SMS Pharmaceuticals Limited — Analyst/Investor Meet Para A-XBRL

NSE 34 min ago·10 Sept 2026, 9:47 am

SMS Pharmaceuticals

SMS Pharmaceuticals has informed stock exchanges that it is scheduled to hold a meeting with analysts and institutional investors. This communication is part of the company's standard disclosure requirements under Para A-XBRL of the listing agreement.

For investors, such meetings are significant as they provide a formal platform for the company to share its business outlook, financial performance, and strategic plans directly with the market. It offers a chance for the management to address key questions and clarify any recent developments.

Investors should watch for any specific guidance or commentary regarding the company's future growth trajectory, which could provide insights into management's confidence levels and operational expectations.